
Cabozantinib Maintenance Fails to Improve PFS in High-Grade Uterine Sarcoma
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNZnU0OTlQZnNlczVBM3l6WWhQb3pQWmNXRF9QM3FESnNXZmNvQU5EbFgtSWhzY21YQVlLa05XV1cyWlNEU1NEeDZlNi1GMVNtaHprdHR6bHhMMHdoYUVUTXEyRzRsaXFlLXhJc2tGZlo1dFVEZXRZXzVtSXdmUDFTT3Q3ZjJIM1RKMks4VmdpVjFlTWtINUgxQURKMDEwQTNnVXJFalB1ZW1PeHkz?oc=5" target="_blank">Cabozantinib Maintenance Fails to Improve PFS in High-Grade Uterine Sarcoma</a>&nbsp;&nbsp;<font color="#6f6f6f">Targeted Oncology</font>
